Practice

IQVIA: Neurologists Are Excited for MS Biosimilars in Europe

April 5th 2023

By Skylar Jeremias

Article

In IQVIA’s latest report, neurologists in Europe reported feeling positive about the biosimilars for multiple sclerosis (MS) coming down the pipeline, showing that industry-wide education efforts and experience with biosimilars are working to instill greater confidence in these products.

Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low

April 3rd 2023

By Skylar Jeremias

Article

Although rheumatologists, dermatologists, and gastroenterologists rated their awareness of adalimumab biosimilars as high, a significant proportion of each group reported that they were not confident prescribing a biosimilar over the originator.

Canadian Province Newfoundland and Labrador Adds Biosimilar Switching Policy

March 28th 2023

By Skylar Jeremias

Article

Newfoundland and Labrador is the latest Canadian province to implement a biosimilar switching policy, following in the footsteps of Ontario and 7 other jurisdictions.

Real-world Studies Show Comparable Outcomes, Higher Discontinuation Rates Between Originators, Biosimilars in RA

March 25th 2023

By Deana Ferreri, PhD

Article

A review of real-world studies assessing patient-reported outcome measures of patients with rheumatoid arthritis (RA) found that although clinical outcomes were similar, patients taking a biosimilar were found to have higher discontinuation rates, possibly as a result of the nocebo effect.

How Community Oncologists Can Break Down Biosimilar Adoption Barriers

March 19th 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.

Retrospective Study Supports Safety of Anti-TNF Biosimilars During Pregnancy

March 18th 2023

By Deana Ferreri, PhD

Article

More and more women are becoming pregnant while on anti–tumor necrosis factor (TNF) biosimilars used to treat inflammatory disorders. However, there is “little data” on the safety and effectiveness of biosimilars in pregnancy, according to authors of a recent retrospective study.

CVS Predicts Interchangeability Won’t Drive Adalimumab Biosimilar Adoption

March 15th 2023

By Skylar Jeremias

Article

In a report from CVS Health, interchangeability will not be a primary factor in driving the adoption of adalimumab biosimilars referencing Humira, contradicting predictions from other sources that believe the designation will impact prescribing habits.

Contributor: FDA Introduces New AI-Based Safety Evaluation Tool to Help Demonstrate Biosimilarity

March 14th 2023

By Sarfaraz K. Niazi, PhD

Article

The FDA's new artificial intelligence (AI)-based modeling on characterizing protein aggregation could directly impact the safety assurance of biosimilars and other therapeutic proteins.

IQVIA's Michael Kleinrock Shares Why Smaller Manufacturers Are Investing in Biosimilar Development

March 12th 2023

By Skylar Jeremias

Video

Better familiarity with biosimilars is enabling government agencies to reevaluate their approval requirements and encouraging smaller manufacturers to invest in biosimilar development, said Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.

Policy Recommendations for Improving Biosimilar Uptake in Belgium

March 11th 2023

By Deana Ferreri, PhD

Article

Increasing the use of biosimilars in Belgium will require realigning financial incentives and providing more information to medical professionals, according to authors of a study that proposed policy recommendations.